ing hormone, y-melanocyte-stimulating hormone, melatonin, motilin, oxytocin (pitocin), pancreatic polypeptide, parathy› roid hormone, placental lactogen, prolactin, prolactin-release inhibiting factor, prolactin-releasing factor, secretin, soma› totropin, somatostatin, growth hormone-release inhibiting factor, thyrotropin (thyroid-stimulating hormone, thyrotro› pin-releasing factor, thyroxine, triiodothyronine, vasoactive intestinal peptide, vasopressin (antidiuretic hormone) and combinations thereof. 

[0122] Particularly preferred analogues of LHRH include buserelin, deslorelin, fertirelin, goserelin, histrelin, leupro› lide (leuprorelin), lutrelin, nafarelin, tryptorelin and combi› nations thereof. 

[0123] Other examples of hormones and hormone-related drugs include anastrozle, betamethasone, bicalutamide, des› mopres sin, desogestrel, dexamethasone, dienestrol, dro› spirenone, estradiol, estropipate, ethinyl estradiol, ethynodiol diaceate, exemestane, fludrocortisone ( e.g., fudrocortisone acetate), goserelin, hydrocortisone, letrozole, leuprolide ( e.g., leuprolide acetate), liothyronine ( e.g., liothyronine sodium), medroxyprogesterone (e.g., medroxyprogesterone acetate), methimazole, methylprednisolone (e.g., methyl› prednisolone acetate), methyl testosterone, norethindrone (e.g., norethindrone acetate), norgestimate, norgestrel, oct› reotide acetate, oxandrolone, oxymetholone, prednisolone, prednisone, progesterone, tamoxifen (e.g., tamoxifen cit› rate), testosterone, and toremifene ( e.g., toremifene citrate). 

[0124] In addition, the peptidyl drug may be a kinin. Par› ticularly preferred kinins include bradykinin, potentiator B, bradykinin potentiator C, kallidin and combinations thereof. 

[0125] Still other peptidyl drugs that provide a desired pharmacological activity can be incorporated into the deliv› ery systems of the invention. Examples include abarelix, adenosine deaminase, anakinra, ancestim, alteplase, algluc› erase, asparaginase, bivalirudin, bleomycin, bombesin, des› mopres sin acetate, des-Q 14-ghrelin, domase-a, enterostatin, erythropoietin, exendin-4, fibroblast growth factor-2, filgrastim, ~-glucocerebrosidase, gonadorelin, hyalu› ronidase, insulinotropin, lepirudin, magainin I, magainin II, nerve growth factor, pentigetide, thrombopoietin, thymosin a-1, thymidin kinase, tissue plasminogen activator, tryp› tophan hydroxylase, urokinase, urotensin II and combina› tions thereof. 

[0126] Particularly preferred systemically active agents that can be administered transdermally in conjunction with the present invention include oxytocin, insulin and LHRH analogues, such as leuprolide. 

[0127] The methods and compositions of the invention are expected to provide an enhanced flux of peptidyl drugs in the range of at least about 6- to 9-fold, preferably at least about 27- to 34-fold, as compared to the flux observed in the absence of the basic enhancers described herein. 

[0128] F. Locally Administered Active Agents 

[0129] Preferred agents for local, topical administration are within the broad classes of compounds known to be topically administrable, including, but not limited to, topical antibiot› ics (e.g., magainin I and magainin II), anti-acne agent, anti› fungal agents, anti-psoriatic agents, antipruritic agents, anti› histamines, antineoplastic agents ( e.g., asparaginase and bleomycin), local anesthetics, anti-inflammatory agents and the like. 

[0130] Suitable topical antibiotic agents include, but are not limited to, antibiotics of the lincomycin family (referring to a class of antibiotic agents originally recovered from strepto- 

myces lincolnensis); antibiotics of the tetracycline family (re› ferring to a class of antibiotic agents originally recovered from streptomyces aureofaciens); sulfur-based antibiotics, i.e., sulfonamides; mupirocin; and antibiotics such as magai› nin I and magainin II. Exemplary antibiotics of the lincomy› cin family include lincomycin itself (6,8-dideoxy-6-[[(1-me› thyl-4-propyl-2-pyrrolidinyl)-carbonyl]amino ]-1-thio-L› threo-a-D-galacto-octopyranoside ), clindamycin, the 7-deoxy, 7-chloro derivative of lincomycin (i.e., 7-chloro-6, 7,8-trideoxy-6-[[ (1-methyl-4-propyl-2-pyrrolidinyl) carbo› nyl]-amino ]-1-thio-L-threo-a-D-galacto-octopyranoside ), related compounds as described, for example, in U.S. Pat. Nos. 3,475,407, 3,509,127, 3,544,551 and 3,513,155, and pharmacologically acceptable salts and esters thereof. Exem› plary antibiotics of the tetracycline family include tetracy› cline itself ( 4-( dimethylamino )-1,4,4a,5,5a,6, 11, 12a-oc› tahydro-3,6, 12, 12a-pentahydroxy-6-methyl-1, 1 ’-dioxo-2- naphthacene-carboxamide ), chlortetracycline, oxytetracycline, tetracycline, demeclocycline, rolitetracy› cline, methacycline and doxycycline and their pharmaceuti› cally acceptable salts and esters, particularly acid addition salts such as the hydrochloride salt. Exemplary sulfur-based antibiotics include, but are not limited to, the sulfonamides sulfacetamide, sulfabenzamide, sulfadiazine, sulfadoxine, sulfamerazine, sulfamethazine, sulfamethizole, sulfamethox› azole, and pharmacologically acceptable salts and esters thereof, e.g., sulfacetamide sodium. 

[0131] Topical anti-acne agents include adapalene, azelaic acid, benzoyl peroxide, clindamycin and clindamycin phos› phate, doxycycline, erythromycin, keratolytics such as sali› cylic acid and retinoic acid (Retin-A"), norgestimate, organic peroxides, retinoids such as isotretinoin and tretinoin, sulfac› etamide sodium, and tazarotene. Preferred anti-acne agents include adapalene, azelaic acid, benzoyl peroxide, clindamy› cin (e.g., clindamycin phosphate), doxycycline (e.g., doxy› cycline monohydrate ), erythromycin, isotretinoin, norgesti› mate, sulfacetamide sodium, tazarotene, and tretinoin. 

[0132] Exemplary topical antifungal agents include amphotericin B, benzoic acid, butenafine and butenafine HCl, butoconazole and butoconazole nitrate, caprylic acid, chloroxylenol, ciclopirox, clotrimazole, econazole and econazole nitrate, fluconazole, itraconazole, ketoconazole, miconazole and miconazole nitrate, naftifine and naftifine HCl, nystatin, oxiconazole and oxiconazole nitrate, salicylic acid, selenium and selenium sulfide, sulconazole and sul› conazole nitrate, terbinafine and terbinafine HCl, tercona› zole, tioconazole, and undecylenic acid. 

[0133] Topical antipsoriatic agents include acitretin, alclometasone dipropionate, anthralin, azathioprine, calcipo› triene, calcitriol, colchicine, cyclosporine, methoxsalen, ret› inoids, and vitamin A. 

[0134] Exemplary local anesthetics include alcohols such as phenol; benzyl benzoate; calamine; chloroxylenol; dyclo› nine; ketamine; menthol; pramoxine; resorcinol; troclosan; and procaine drugs such as benzocaine, bupivacaine, chloro› procaine, cinchocaine, cocaine, dexivacaine, diamocaine, dibucaine, etidocaine, hexylcaine, levobupivacaine, lidocaine, mepivacaine, oxethazaine, prilocalne, procaine, proparacaine, propoxycaine, pyrrocaine, risocaine, rodocaine, ropivacaine, and tetracaine; and combinations thereof. Derivatives of these compounds, such as pharmaceu› tically acceptable salts and esters are also of particular inter› est, for example, bupivacaine HCl, chloroprocaine HCl, diamocaine cyclamate, dibucaine HCl, dyclonine HCl, eti- 

